Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Cyclacel Pharmaceuticals. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Cyclacel Pharmaceuticals's earnings available for a low price, and how does
this compare to other companies in the same industry?
Unable to determine if Cyclacel Pharmaceuticals is high growth as no earnings estimate data is available.
Cyclacel Pharmaceuticals's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Cyclacel Pharmaceuticals's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Cyclacel Pharmaceuticals's finances.
The net worth of a company is the difference between its assets and liabilities.
Cyclacel Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Cyclacel Pharmaceuticals's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Cyclacel Pharmaceuticals's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Cyclacel Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Spiro George Rombotis has been President of Cyclacel Pharmaceuticals Inc. (formerly, Cyclacel Group Plc) since August 1997 and has been its Founding Chief Executive Officer since joining in August 1997. Mr. Rombotis also serves as Chief Executive of Cyclacel Limited. He has over 23 years of experience with pharmaceutical and biotechnology companies. He served as Chief Executive Officer and President of Xcyte Therapies Inc. Previously, he served as Vice President of International Operations and Business Development, Managing Director, Europe of Japanese joint venture, at The Liposome Company, Inc. He served as Vice President of Pharmaceuticals for Central and Eastern Europe and as Director of International Marketing of Bristol-Myers Squibb Company. He began his career in pharmaceuticals in Switzerland at the business development group of Ciba-Geigy AG, subsequently Novartis AG. He served as Head of European Marketing and Sales and Head of Corporate Development of Janssen Biotech, Inc. (formerly Centocor, Inc.) as well as working in Business Development of Novartis AG. He serves as a Director of BioNJ Inc. He has been Executive Director of Cyclacel Pharmaceuticals, Inc since March 2006. He serves on the Kellogg Biotech Advisory Board. He served as Director of Xcyte Therapies Inc. and Japanese joint venture, at Liposome Company, Inc. Mr. Rombotis holds a B.A. from Williams College, an M.B.A. and Master's degree in Hospital Management with honors, from the Kellogg Graduate School of Management.
Spiro's compensation has increased whilst company is loss making.
Spiro's remuneration is higher than average for companies of similar size in Germany.
Executive VP of Finance
Vice President of Clinical Development & Regulatory Affairs
Director of Human Resources
Head of Preclinical Development and Vice President of Chemistry & Preclinical Development
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Cyclacel Pharmaceuticals board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company’s oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes. Its oncology development programs also comprise Seliciclib, a first-generation cyclin dependent kinase (CDK) inhibitor that is in phase I/II combination study with sapacitabine for BRCA mutations; and CYC065, a second generation CDK inhibitor, which is in Phase I clinical trial for solid tumors. In addition, the company’s oncology development programs include CYC140, a polo-like kinase inhibitor program that is in preclinical development stage. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.